| 摘要 |
FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention describes novel derivatives of condensed 1,2,4-thiadiazine of the general formula (I) given in the description where B means one of bonds in double bond between atoms 2 and 3 of ring of the formula (I); D means -S(=O)2-; R1 means hydrogen atom; R4 means hydrogen atom; or R4 in common with R5 means one of bonds in double bond between atoms 2 and 3 of the formula (I); or R1 in common with R4 means one of bonds in double bond between atoms 3 and 4 of the formula (I); R2 means hydrogen atom, C1-6-alkyl, C3-6-cycloalkyl, C2-6-alkenyl; R3 means R8, aryl substituted with C1-6-alkyl where R8 means hydrogen atom, C3-6-cycloalkyl or (C3-6-cycloalkyl)-C1-6-alkyl, unbranched or branched C1-18-alkyl, with optionally mono- or polysubstituted hydroxy-group, C3-6-cycloalkyl, aryl, carboxy-group; A in common with 5 and 6 carbon atoms of the formula (I) means 5-membered heterocyclic system containing one or two nitrogen atoms or one sulfur atom being heterocyclic systems are optionally mono- or poly-substituted with halogen atom under condition of excluding the following compounds: 3-aminoimidazo-[4,5-e] -1,2,4-thiadiazine 1,1-dioxide and 3-(benzoylamino)-imidazo-[4,5-e] -1,2,4-thiadiazine 1,1-dioxide or its salt with pharmaceutically acceptable acid or base. New compounds are used as agents opening KATF-regulated potassium channels. Also, invention describes pharmaceutical composition eliciting effect on KATF-regulated potassium channels and method of effect on KATF-regulated channels. EFFECT: improved method of synthesis, valuable medicinal properties of compounds. 18 cl, 23 ex |
